Enara Bio’s mission is to shine a light on unconventional targets and develop the next generation of cancer immunotherapies designed to treat a broad patient population. Enara Bio is exploring the hidden depths of cancer and T-cell biology to discover and characterize novel immunotherapy targets, such as MR1-presented ligands and Dark Antigens™, which arise from altered cellular processes in cancer cells.

Biotechnology

Enara Bio

Anonymous

Adam Taylor

Jonathan Porter

Sophie Papa

Soreya Senior

Duncan Howie

Andrew Fadden

Luke Williams

Ray Duffy

Simon Jarvis

Jo Senra

Ron Wolchinsky

Bethany Turner

Nicola Ternette

Fabio Marino

Charlotte Howard

Joseph Dukes

Jonathon Dines

David Watson

The Scientific Advisory Board at Enara Bio provides expert guidance and strategic insights to advance the company's research and development efforts. Comprised of leading scientists in the field, the board advises on the scientific validity and potential impact of novel immunotherapy targets, such as MR1-presented ligands and Dark Antigens™, ensuring that Enara Bio's innovations align with current scientific advancements and clinical needs.

Scientific Advisory Board

Research and Development

Directors

Leadership Team

Scientific Advisory Board

About

Team members

Other teams at Enara Bio

Research and Development

Directors

Leadership Team